| Issue | Title | |
| Vol 2013, No 3 (2013) | Mylan Bolsters Global Injectables Business with Deal to Acquire Agila Specialities from Strides Arcolab | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 7 (2009) | Mylan Enters Generic Biologicals Market | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 84 (2007) | Mylan to Acquire Generics Business of Merck KGaA | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | Mylan to Acquire King for US$4 B | Abstract |
| Business Review Editor | ||
| Vol 2004, No 51 (2004) | Mylan to Acquire King for US$4 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | Myogen's Unpopular Ambrisentan Deal with GSK | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 8 (2009) | Nabi Biopharm Sells PentaStaph™ to GSK | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 80 (2007) | Nanotechnology for Drug Delivery: A Validated Technology? | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 6 (2015) | NantPharma to Acquire Third-Generation Paclitaxel from Sorrento Therapeutics in Potential US$1.3 B Deal | Abstract |
| Heather Cartwright & Tridisha Goswami | ||
| Vol 2006, No 74 (2006) | Nastech and Amylin Sign Deal for Diabetes Nasal Spray | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | Nastech and Merck to Co-Develop Nasal Spray for Obesity | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Nearly | Details jpg |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Nearly | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 96 (2008) | Needle-free Vaccines Lead Intercell to the US with its Latest Acquisition | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2008, No 99 (2008) | Negotiations Begin Between Bristol-Myers Squibb and ImClone | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2012, No 12 (2012) | Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 67 (2006) | Neupro (rotigotine) | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 46 (2004) | Neurocrine Acquires Wyeth’s Financial Interest in Indiplon | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 2 (2019) | Neurocrine Adds Four Gene Therapies to Pipeline with Voyager Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 24 (2002) | Neurocrine and Wyeth extend EAAT-3 agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 7 (2020) | Neurocrine Biosciences Licenses Seven Psychiatric Programmes from Takeda in US$2 B Deal | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2021, No 11 (2021) | Neurocrine Collaborates with Sosei Heptares for Neuropsychiatric Drugs | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2017, No 4 (2017) | Neurocrine gains BIAL’s Parkinson’s asset Opicapone for North America | Abstract pdf html |
| Vipul Sikka | ||
| Vol 2010, No 7 (2010) | Neurocrine Improves Financial Position by Partnering with Abbott and Boehringer Ingelheim | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 12 (2019) | Neurocrine Signs US$1.7 B Epilepsy Pact with Xenon | Abstract pdf html |
| Michelle Liu | ||
| Vol 2009, No 7 (2009) | NeurogesX and Astellas Enter into Commercialisation Agreement for Pain Patch | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 70 (2006) | Neuromed Pharmaceuticals and Merck Collaborate for Novel Pain Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | NeuroSearch A/S | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | NeuroSearch and GSK in Depression Deal | Abstract |
| Business Review Editor | ||
| Vol 2009, No 8 (2009) | NeuroSearch and Janssen Collaborate on CNS Developments | Abstract |
| Taskin Ahmed | ||
| Vol 2002, No 24 (2002) | New Chemical Entities as Potential Opportunities for Drug Delivery Companies | Abstract |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | New Distributor for Cedax® in the US | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 11 (2014) | NewLink Genetics Finds Collaborator in Genentech for IDO Pathway Inhibitors | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 6 (2012) | Newron Moves to Acquire Swedish Neurogenesis Company NeuroNova | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 64 (2005) | NexMed Signs Global Licensing Deal with Novartis | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Nicotine patches | Details jpg |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | NicOx SA | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 3 (2012) | NicOx Targets Ophthalmology with Altacor Buyout Option | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 70 (2006) | NicOx Upgrades Preclinical Deals | Abstract |
| Business Review Editor | ||
| Vol 2004, No 54 (2004) | Nippon Shinyaku Out-Licenses Cancer and Stroke Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 102 (2008) | NitroMed and Archemix Sign Reverse Merger Deal | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2008, No 98 (2008) | No More Sleepless Nights For Actelion? | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2004, No 43 (2004) | Norwood Abbey Licenses Technology to TAP Pharmaceutical Products | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Novacea Licences Cancer Therapy to Schering-Plough for US$452 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 100 (2008) | Novacea Rescued by Transcept | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2024, No 11 (2024) | Novartis Acquires Gene Therapy Specialist Kate Therapeutics in US$1.1 B Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2010, No 8 (2010) | Novartis Acquires Option to Phase II siRNA Drug from Quark Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 2 (2011) | Novartis Advances its Capabilities in Personalised Medicine with Genoptix Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 5 (2010) | Novartis and Array Agree MEK Inhibitor Deal Worth up to USD 467 M | Abstract |
| Debbie Tranter | ||
| Vol 2008, No 103 (2008) | Novartis and Evotec to Identify and Develop Small Molecules | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2014, No 5 (2014) | Novartis and GSK Shift M&A Paradigm with Trio of Deals | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 61 (2005) | Novartis and Hybridon to Develop Oligonucleotides for Asthma and Allergy | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 11 (2018) | Novartis and Pfizer to Explore NASH Combinations | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 71 (2006) | Novartis and SGX Sign Oncology Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 8 (2012) | Novartis and University of Pennsylvania in Broad Cancer Immunotherapy Alliance | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 64 (2005) | Novartis Backs Alnylam and RNAi | Abstract |
| Business Review Editor | ||
| Vol 2016, No 7 (2016) | Novartis bolsters its immuno-oncology pipeline with Xencor’s bispecific antibodies | Abstract pdf html |
| Natasha Berry | ||
| Vol 2017, No 1 (2017) | Novartis Bolsters NASH Pipeline with a Deal with Conatus | Abstract html pdf |
| Subham Nandi | ||
| Vol 2017, No 11 (2017) | Novartis Bolsters Oncology Portfolio with US$3.9 B Purchase of AAA | Abstract html pdf |
| Arun Manohar & Heather Cartwright | ||
| Vol 2015, No 8 (2015) | Novartis Bolts on Spinifex to Bolster its Neuroscience Franchise | Abstract html |
| Heather Cartwright & Hardik Mewada | ||
| Vol 2019, No 4 (2019) | Novartis Boosts Immunology Investment with IFM Tre Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2009, No 12 (2009) | Novartis Boosts its Oncology Position | Abstract |
| Taskin Ahmed | ||
| Vol 2003, No 35 (2003) | Novartis Builds Antiviral Franchise with Idenix Pharmaceuticals | Abstract |
| Business Review Editor | ||
| Vol 2018, No 10 (2018) | Novartis Builds on Radiopharmaceuticals Platform with Endocyte Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2023, No 6 (2023) | Novartis Buys Avrobio’s Rare Disease Gene Therapy for US$87.5 M | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 7 (2009) | Novartis Buys Ebewe in Oncology Generics Push | Abstract |
| Taskin Ahmed | ||
| Vol 2019, No 11 (2019) | Novartis Buys The Medicines Company for US$9.7 B | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 60 (2005) | Novartis Chooses the UK for High-Value COPD Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 6 (2022) | Novartis Collaborates with Precision Bio in Gene Editing Pact | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 7 (2025) | Novartis Collaborates with ProFound Therapeutics to Develop Cardiovascular Therapies | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2015, No 10 (2015) | Novartis Comes to the Rescue of Xoma with TGFb Antibody Licensing Deal | Abstract pdf html |
| Heather Cartwright & Keshav Mahawar | ||
| Vol 2009, No 10 (2009) | Novartis Deals Add New Antibiotic and Discovery Programme | Abstract |
| Taskin Ahmed | ||
| Vol 2022, No 3 (2022) | Novartis Delves Further into AAV Gene Therapies with US$1.65 B Voyager Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2016, No 12 (2016) | Novartis Exercises Option to Acquire Selexys Pharmaceuticals to Add Sickle Cell Disease Candidate | Abstract pdf html |
| Keshav Mahawar | ||
| Vol 2010, No 1 (2010) | Novartis Exercises Option to Buy out Alcon | Abstract |
| Taskin Ahmed | ||
| Vol 2005, No 58 (2005) | Novartis Expands Generics Business | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 97 (2008) | Novartis Gains MRSA Product Through Acquisition of Protez Pharmaceuticals | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2010, No 3 (2010) | Novartis in Novel Therapeutic Cancer Vaccine Deal with Transgene | Abstract |
| PharmaDeals Analyst | ||
| Vol 2007, No 86 (2007) | Novartis in Takeover Mood | Abstract |
| Business Review Editor | ||
| Vol 2007, No 84 (2007) | Novartis In-licenses Cytos#8217; Smoking Vaccine | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 5 (2017) | Novartis In-Licenses Dry-eye Drug to Challenge Shire and Allergan | Abstract pdf html |
| Natasha Piper | ||
| Vol 2021, No 2 (2021) | Novartis Licenses Anti-PD1 Antibody Tislelizumab from BeiGene in US$2.2 B Deal | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2020, No 11 (2020) | Novartis Licenses Mesoblast’s Stem Cell Therapy Remestemcel-L | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 71 (2006) | Novartis Licenses Novel Drug for Hepatitis C Infection | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Novartis Looks to Combination Alliances to Strengthen its Hepatitis C Therapeutics Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 4 (2024) | Novartis Pays Arvinas US$150 M Upfront for Prostate Cancer Protein Degrader | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 11 (2023) | Novartis Pays US$100 M Upfront for Legend Biotech’s CAR-T Cell Therapies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2024, No 11 (2024) | Novartis Pays US$150 M Upfront for Monte Rosa’s Molecular Glue Degrader | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 2 (2009) | Novartis Pays US$75 M for Portola's Anticoagulant | Abstract html |
| Taskin Ahmed | ||
| Vol 2025, No 2 (2025) | Novartis Regains Abelacimab Through US$3.1 B Acquisition of Anthos Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2021, No 11 (2021) | Novartis Rejoins Protein Degradation Space with US$1.3 B Dunad Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 11 (2009) | Novartis Sets Eyes on Chinese Vaccine Market | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 70 (2006) | Novartis Signs Cancer Deal with Infinite Promise | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 12 (2022) | Novartis Signs License Agreement with MorphoSys to Develop and Commercialise Preclinical Inhibitors for Cancer | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2023, No 4 (2023) | Novartis Signs US$1.7 B Deal with Bicycle Therapeutics for Cancer Radiopharmaceuticals | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2025, No 9 (2025) | Novartis Signs US$2.2 B Deal with Arrowhead Pharmaceuticals for RNAi Therapy | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 4 (2018) | Novartis Spends US$8.7 B on Gene Therapy Biotech AveXis | Abstract pdf html |
| Natasha Piper | ||
| Vol 2009, No 12 (2009) | Novartis Strengthens Cardiovascular Portfolio | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 98 (2008) | Novartis Takes Back Tekturna | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2007, No 88 (2007) | Novartis Takes option on Radius’ Osteoporosis Drug | Abstract pdf |
| Business Review Editor | ||
| 1701 - 1800 of 2613 Items | << < 13 14 15 16 17 18 19 20 21 22 > >> | |